Document is current
Any future updates will be listed below
-
Authors
So, Kaman
Saferali, Aabida
Yun, Jeong H. https://orcid.org/0000-0002-4361-8295
Ryu, Min Hyung https://orcid.org/0000-0003-3071-7363
Schiavi, Enrico https://orcid.org/0009-0003-3954-8620
Castaldi, Peter J.
Ruvuna, Lisa https://orcid.org/0000-0002-3800-511X
Bowler, Russell P. https://orcid.org/0000-0003-4651-363X
Curtis, Jeffrey L. https://orcid.org/0000-0001-5191-4847
Hersh, Craig P. https://orcid.org/0000-0002-1342-4334
-
Funding
Funding for this research was provided by:
National Institutes of Health (U01HL089897)
National Institutes of Health (R01HL137995)
National Institutes of Health (R01HL166231)
- License Information
-
More Information
Article History
Received: 12 January 2026
Accepted: 12 March 2026
First Online: 18 March 2026
Declarations
:
: COPDGene was approved by the Institutional Review Board at Mass General Brigham and all participating centers. The research was conducted in accordance with the Belmont Report.
: Not applicable.
: JHY reports consulting fees from Bridge BioTherapeutics and serving on an Advisory Board for Genentech. PJC reports grants from Sanofi and Bayer, and consulting fees from Verona Pharma and Genentech. JLC reports grants from the COPD Foundation, consulting fees from AstraZeneca and participation on Data Safety Monitoring Board or Advisory Board for Novartis and Genetech. CPH reports grants from the Alpha-1 Foundation and Bayer, and consulting fees from Apogee Therapeutics, AstraZeneca, Chiesi, Genentech, Ono Pharma, Sanofi, Takeda, and Verona Pharma. None of the other authors report any conflicts of interest.
